{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T13:21:12Z","timestamp":1790688072239,"version":"4.1.0"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Tumor Biol."],"published-print":{"date-parts":[[2011,12]]},"DOI":"10.1007\/s13277-011-0204-3","type":"journal-article","created":{"date-parts":[[2011,8,23]],"date-time":"2011-08-23T19:07:33Z","timestamp":1314126453000},"page":"1087-1095","source":"Crossref","is-referenced-by-count":139,"title":["HE4 a novel tumour marker for ovarian cancer: comparison with CA 125 and ROMA algorithm in patients with gynaecological diseases"],"prefix":"10.1007","volume":"32","author":[{"given":"Rafael","family":"Molina","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jose M.","family":"Escudero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jose M.","family":"Aug\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xavier","family":"Filella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Foj","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aureli","family":"Torn\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jose","family":"Lejarcegui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jaume","family":"Pahisa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2011,8,24]]},"reference":[{"issue":"Suppl 1","key":"204_CR1","doi-asserted-by":"crossref","first-page":"S247","DOI":"10.1016\/S0020-7292(06)60040-4","volume":"95","author":"RT Penson","year":"2006","unstructured":"Penson RT, Wenzel LB, Vergote I, Cella D. Quality of life considerations in gynecologic cancer. FIGO 6th Annual Report on the Results of Treatment in Gynecological Cancer. Int J Gynaecol Obstet. 2006;95 Suppl 1:S247\u201357.","journal-title":"Int J Gynaecol Obstet"},{"key":"204_CR2","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1074\/mcp.R400006-MCP200","volume":"3","author":"IJ Jacobs","year":"2004","unstructured":"Jacobs IJ, Menon U. Progress and challenges in screening for early detection of ovarian cancer. Mol Cell Proteomics. 2004;3:355\u201366.","journal-title":"Mol Cell Proteomics"},{"key":"204_CR3","doi-asserted-by":"crossref","first-page":"43","DOI":"10.3322\/canjclin.57.1.43","volume":"57","author":"A Jemal","year":"2007","unstructured":"Jemal A, Siegel R, Ward E, Murray T, Xu J, Thun MJ. Cancer statistics. CA Cancer J Clin. 2007;57:43\u201366.","journal-title":"CA Cancer J Clin"},{"issue":"Suppl 3","key":"204_CR4","first-page":"274","volume":"15","author":"RC Bast Jr","year":"2005","unstructured":"Bast Jr RC, Badgwell D, Lu Z, Marquez R, Rosen D, Liu J, et al. New tumour markers: CA 125 and beyond. Int J Gynecol Cancer. 2005;15 Suppl 3:274\u201381.","journal-title":"Int J Gynecol Cancer"},{"key":"204_CR5","first-page":"2807","volume":"19","author":"European Group on Tumour Markers","year":"1999","unstructured":"European Group on Tumour Markers. Tumour markers in gynaecological cancers\u2014EGTM recommendations. Anticancer Res. 1999;19:2807\u201310.","journal-title":"Anticancer Res"},{"key":"204_CR6","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1111\/j.1525-1438.2005.00130.x","volume":"15","author":"MJ Duffy","year":"2005","unstructured":"Duffy MJ, Bonfrer JM, Kulpa J, Rustin GJ, Soletormos G, Torre GC, et al. CA 125 in ovarian cancer: European Group on Tumour Markers guidelines for clinical use. Int J Gynecol Cancer. 2005;15:679\u201391.","journal-title":"Int J Gynecol Cancer"},{"key":"204_CR7","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1097\/00003081-200609000-00004","volume":"49","author":"AN Rosenthal","year":"2006","unstructured":"Rosenthal AN, Menon U, Jacobs IJ. Screening for ovarian cancer. Clin Obstet Gynecol. 2006;49:433\u201347.","journal-title":"Clin Obstet Gynecol"},{"key":"204_CR8","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/j.ygyno.2005.06.040","volume":"99","author":"DG Rosen","year":"2005","unstructured":"Rosen DG, Wang L, Atkinson JN, Yu Y, Lu KH, Diamandis EP, et al. Potential markers that complement expression of CA 125 in epithelial ovarian cancer. Gynecol Oncol. 2005;99:267\u201377.","journal-title":"Gynecol Oncol"},{"key":"204_CR9","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.ygyno.2008.08.031","volume":"112","author":"RG Moore","year":"2009","unstructured":"Moore RG, McMeekin DS, Brown AK, DiSilvestro P, Miller MC, Allard WJ, et al. A novel multiple marker bioassay utilizing HE4 and CA 125 for the prediction of ovarian cancer in patients with a pelvic mass. Gynecol Oncol. 2009;112:40\u20136.","journal-title":"Gynecol Oncol"},{"key":"204_CR10","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1016\/j.ygyno.2009.09.041","volume":"116","author":"RG Moore","year":"2010","unstructured":"Moore RG, Maclaughlan S, Bast Jr RC. Current state of biomarker development for clinical application in epithelial ovarian cancer. Gynecol Oncol. 2010;116:240\u20135.","journal-title":"Gynecol Oncol"},{"key":"204_CR11","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1016\/0002-9378(84)90035-8","volume":"149","author":"RC Bast Jr","year":"1984","unstructured":"Bast Jr RC, Klug TL, Schaetzl E, Lavin P, Niloff JM, Greber TF, et al. Monitoring human ovarian carcinoma with a combination of CA 125, CA 19\u20139, and carcinoembryonic antigen. Am J Obstet Gynecol. 1984;149:553\u20139.","journal-title":"Am J Obstet Gynecol"},{"key":"204_CR12","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1093\/clinchem\/44.7.1379","volume":"44","author":"HA Fritsche","year":"1998","unstructured":"Fritsche HA, Bast RC. CA 125 in ovarian cancer: advances and controversy. Clin Chem. 1998;44:1379\u201380.","journal-title":"Clin Chem"},{"key":"204_CR13","doi-asserted-by":"crossref","first-page":"e11","DOI":"10.1373\/clinchem.2008.105601","volume":"54","author":"CM Sturgeon","year":"2008","unstructured":"Sturgeon CM, Duffy MJ, Stenman UH, Lilja H, Brunner N, Chan DW, et al. National Academy of Clinical Biochemistry laboratory medicine practice guidelines for use of tumour markers in testicular, prostate, colorectal, breast, and ovarian cancers. Clin Chem. 2008;54:e11\u201379.","journal-title":"Clin Chem"},{"key":"204_CR14","doi-asserted-by":"crossref","first-page":"1630","DOI":"10.1016\/j.ajog.2005.05.005","volume":"193","author":"SS Buys","year":"2005","unstructured":"Buys SS, Partridge E, Greene MH, Prorok PC, Reding D, Riley TL, et al. Ovarian cancer screening in the Prostate, Lung, Colorectal and Ovarian (PLCO) cancer screening trial: findings from the initial screen of a randomized trial. Am J Obstet Gynecol. 2005;193:1630\u20139.","journal-title":"Am J Obstet Gynecol"},{"key":"204_CR15","first-page":"609","volume":"30","author":"A Dalen van","year":"2009","unstructured":"van Dalen A, Favier J, Hallensleben E, Burges A, Stieber P, de Bruijn HW, et al. Significance of serum CA 125 and TPS antigen levels for determination of overall survival after three chemotherapy courses in ovarian cancer patients during long-term follow-up. Eur J Gynaecol Oncol. 2009;30:609\u201315.","journal-title":"Eur J Gynaecol Oncol"},{"key":"204_CR16","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1159\/000217776","volume":"13","author":"R Molina","year":"1992","unstructured":"Molina R, Ojeda B, Filella X, Borras G, Jo J, Mas E, et al. A prospective study of tumour markers CA 125 and CA 19.9 in patients with epithelial ovarian carcinomas. Tumour Biol. 1992;13:278\u201386.","journal-title":"Tumour Biol"},{"key":"204_CR17","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1159\/000181180","volume":"29","author":"R Molina","year":"2008","unstructured":"Molina R, Auge JM, Escudero JM, Marrades R, Vinolas N, Carcereny E, et al. Mucins CA 125, CA 19.9, CA 15.3 and TAG-72.3 as tumour markers in patients with lung cancer: comparison with CYFRA 21\u20131, CEA, SCC and NSE. Tumour Biol. 2008;29:371\u201380.","journal-title":"Tumour Biol"},{"key":"204_CR18","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1159\/000224628","volume":"30","author":"R Molina","year":"2009","unstructured":"Molina R, Auge JM, Bosch X, Escudero JM, Vinolas N, Marrades R, et al. Usefulness of serum tumour markers, including progastrin-releasing peptide, in patients with lung cancer: correlation with histology. Tumour Biol. 2009;30:121\u20139.","journal-title":"Tumour Biol"},{"key":"204_CR19","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1016\/0028-2243(85)90130-3","volume":"19","author":"RC Bast Jr","year":"1985","unstructured":"Bast Jr RC, Knapp RC. Use of the CA 125 antigen in diagnosis and monitoring of ovarian carcinoma. Eur J Obstet Gynecol Reprod Biol. 1985;19:354\u20136.","journal-title":"Eur J Obstet Gynecol Reprod Biol"},{"key":"204_CR20","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1093\/clinchem\/37.8.1379","volume":"37","author":"R Molina","year":"1991","unstructured":"Molina R, Filella X, Bruix J, Mengual P, Bosch J, Calvet X, et al. Cancer antigen 125 in serum and ascitic fluid of patients with liver diseases. Clin Chem. 1991;37:1379\u201383.","journal-title":"Clin Chem"},{"key":"204_CR21","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1159\/000071198","volume":"65","author":"A Sevinc","year":"2003","unstructured":"Sevinc A, Camci C, Turk HM, Buyukberber S. How to interpret serum CA 125 levels in patients with serosal involvement? A clinical dilemma. Oncology. 2003;65:1\u20136.","journal-title":"Oncology"},{"key":"204_CR22","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1159\/000081392","volume":"25","author":"J Trape","year":"2004","unstructured":"Trape J, Molina R, Sant F. Clinical evaluation of the simultaneous determination of tumour markers in fluid and serum and their ratio in the differential diagnosis of serous effusions. Tumour Biol. 2004;25:276\u201381.","journal-title":"Tumour Biol"},{"key":"204_CR23","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1007\/s13277-010-0049-1","volume":"31","author":"E Anastasi","year":"2010","unstructured":"Anastasi E, Granato T, Marchei GG, Viggiani V, Colaprisca B, Comploj S, et al. Ovarian tumour marker HE4 is differently expressed during the phases of the menstrual cycle in healthy young women. Tumour Biol. 2010;31:411\u20135.","journal-title":"Tumour Biol"},{"key":"204_CR24","first-page":"3695","volume":"63","author":"I Hellstrom","year":"2003","unstructured":"Hellstrom I, Raycraft J, Hayden-Ledbetter M, Ledbetter JA, Schummer M, McIntosh M, et al. The HE4 (WFDC2) protein is a biomarker for ovarian carcinoma. Cancer Res. 2003;63:3695\u2013700.","journal-title":"Cancer Res"},{"key":"204_CR25","doi-asserted-by":"crossref","first-page":"2768","DOI":"10.1038\/sj.onc.1205363","volume":"21","author":"L Bingle","year":"2002","unstructured":"Bingle L, Singleton V, Bingle CD. The putative ovarian tumour marker gene HE4 (WFDC2), is expressed in normal tissues and undergoes complex alternative splicing to yield multiple protein isoforms. Oncogene. 2002;21:2768\u201373.","journal-title":"Oncogene"},{"key":"204_CR26","doi-asserted-by":"crossref","first-page":"2162","DOI":"10.1158\/0008-5472.CAN-04-3924","volume":"65","author":"R Drapkin","year":"2005","unstructured":"Drapkin R, von Horsten HH, Lin Y, Mok SC, Crum CP, Welch WR, et al. Human epididymis protein 4 (HE4) is a secreted glycoprotein that is overexpressed by serous and endometrioid ovarian carcinomas. Cancer Res. 2005;65:2162\u20139.","journal-title":"Cancer Res"},{"key":"204_CR27","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1038\/modpathol.3800612","volume":"19","author":"MT Galgano","year":"2006","unstructured":"Galgano MT, Hampton GM, Frierson Jr HF. Comprehensive analysis of HE4 expression in normal and malignant human tissues. Mod Pathol. 2006;19:847\u201353.","journal-title":"Mod Pathol"},{"key":"204_CR28","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1016\/j.ygyno.2007.10.017","volume":"108","author":"RG Moore","year":"2008","unstructured":"Moore RG, Brown AK, Miller MC, Skates S, Allard WJ, Verch T, et al. The use of multiple novel tumour biomarkers for the detection of ovarian carcinoma in patients with a pelvic mass. Gynecol Oncol. 2008;108:402\u20138.","journal-title":"Gynecol Oncol"},{"key":"204_CR29","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1038\/sj.bjc.6605011","volume":"100","author":"K Huhtinen","year":"2009","unstructured":"Huhtinen K, Suvitie P, Hiissa J, Junnila J, Huvila J, Kujari H, et al. Serum HE4 concentration differentiates malignant ovarian tumours from ovarian endometriotic cysts. Br J Cancer. 2009;100:1315\u20139.","journal-title":"Br J Cancer"},{"key":"204_CR30","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1016\/j.ygyno.2008.04.002","volume":"110","author":"RG Moore","year":"2008","unstructured":"Moore RG, Brown AK, Miller MC, Badgwell D, Lu Z, Allard WJ, et al. Utility of a novel serum tumour biomarker HE4 in patients with endometrioid adenocarcinoma of the uterus. Gynecol Oncol. 2008;110:196\u2013201.","journal-title":"Gynecol Oncol"},{"key":"204_CR31","unstructured":"Escudero JM, Auge JM, Filella X, Torne A, Pahisa J, Molina R. The utility of serum human epididymis protein 4 (HE4) in patients with malignant and non malignant diseases: comparison with CA 125. Clin Chem. 2011 (in press)"},{"key":"204_CR32","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1007\/s13277-009-0015-y","volume":"31","author":"E Anastasi","year":"2010","unstructured":"Anastasi E, Marchei GG, Viggiani V, Gennarini G, Frati L, Reale MG. HE4: a new potential early biomarker for the recurrence of ovarian cancer. Tumour Biol. 2010;31:113\u20139.","journal-title":"Tumour Biol"},{"key":"204_CR33","doi-asserted-by":"crossref","first-page":"228\u20136","DOI":"10.1016\/j.ajog.2010.03.043","volume":"203","author":"RG Moore","year":"2010","unstructured":"Moore RG, Jabre-Raughley M, Brown AK, Robison KM, Miller MC, Allard WJ, et al. Comparison of a novel multiple marker assay vs the Risk of Malignancy Index for the prediction of epithelial ovarian cancer in patients with a pelvic mass. Am J Obstet Gynecol. 2010;203:228\u20136.","journal-title":"Am J Obstet Gynecol"},{"key":"204_CR34","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1016\/j.ygyno.2010.02.005","volume":"117","author":"B Nolen","year":"2010","unstructured":"Nolen B, Velikokhatnaya L, Marrangoni A, De Geest K, Lomakin A, Bast Jr RC, et al. Serum biomarker panels for the discrimination of benign from malignant cases in patients with an adnexal mass. Gynecol Oncol. 2010;117:440\u20135.","journal-title":"Gynecol Oncol"},{"key":"204_CR35","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1007\/978-0-387-68969-2_2","volume":"622","author":"I Hellstrom","year":"2008","unstructured":"Hellstrom I, Hellstrom KE. SMRP and HE4 as biomarkers for ovarian carcinoma when used alone and in combination with CA 125 and\/or each other. Adv Exp Med Biol. 2008;622:15\u201321.","journal-title":"Adv Exp Med Biol"},{"key":"204_CR36","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1002\/jcla.20340","volume":"23","author":"M Montagnana","year":"2009","unstructured":"Montagnana M, Lippi G, Ruzzenente O, Bresciani V, Danese E, Scevarolli S, et al. The utility of serum human epididymis protein 4 (HE4) in patients with a pelvic mass. J Clin Lab Anal. 2009;23:331\u20135.","journal-title":"J Clin Lab Anal"},{"key":"204_CR37","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1038\/sj.bjc.6605119","volume":"101","author":"M Montagnana","year":"2009","unstructured":"Montagnana M, Lippi G, Danese E, Franchi M, Guidi GC. Usefulness of serum HE4 in endometriotic cysts. Br J Cancer. 2009;101:548.","journal-title":"Br J Cancer"},{"key":"204_CR38","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.ejogrb.2008.12.015","volume":"143","author":"E Petru","year":"2009","unstructured":"Petru E, HJ Lu ck, Stuart G, Gaffney D, Millan D, Vergote I. Gynecologic Cancer Intergroup (GCIG) proposals for changes of the current FIGO staging system. Eur J Obstet Gynecol Reprod Biol. 2009;143:69\u201374.","journal-title":"Eur J Obstet Gynecol Reprod Biol"},{"key":"204_CR39","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1373\/49.3.433","volume":"49","author":"C Stephan","year":"2003","unstructured":"Stephan C, Wesseling S, Schink T, Jung K. Comparison of eight computer programs for receiver-operating characteristic analysis. Clin Chem. 2003;49:433\u20139.","journal-title":"Clin Chem"},{"issue":"5","key":"204_CR40","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1038\/sj.bjc.6606092","volume":"104","author":"T Gorp Van","year":"2011","unstructured":"Van Gorp T, Cadron I, Despierre E, Daemen A, Leunen K, Amant F, et al. HE4 and CA 125 as a diagnostic test in ovarian cancer: prospective validation of the risk of ovarian malignancy algorithm. Br J Cancer. 2011;104(5):863\u201370.","journal-title":"Br J Cancer"},{"issue":"3","key":"204_CR41","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1515\/CCLM.2011.075","volume":"49","author":"M Montagnana","year":"2011","unstructured":"Montagnana M, Danese E, Ruzzenente O, Bresciani V, Nuzzo T, Gelati M, et al. The ROMA (Risk of Ovarian Malignancy Algorithm) for estimating the risk of epithelial ovarian cancer in women presenting with pelvic mass: is it really useful? Clin Chem Lab Med. 2011;49(3):521\u20135.","journal-title":"Clin Chem Lab Med"}],"container-title":["Tumor Biology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.springerlink.com\/index\/pdf\/10.1007\/s13277-011-0204-3","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,6,22]],"date-time":"2020-06-22T15:17:11Z","timestamp":1592839031000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s13277-011-0204-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,8,24]]},"references-count":41,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2011,12]]}},"alternative-id":["204"],"URL":"https:\/\/doi.org\/10.1007\/s13277-011-0204-3","relation":{},"ISSN":["1010-4283","1423-0380"],"issn-type":[{"value":"1010-4283","type":"print"},{"value":"1423-0380","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,8,24]]}}}